GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Total Equity

MedMira (MedMira) Total Equity : $-11.98 Mil (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Total Equity?

MedMira's total equity for the quarter that ended in Jan. 2024 was $-11.98 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


MedMira Total Equity Historical Data

The historical data trend for MedMira's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Total Equity Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.31 -11.53 -12.55 -9.55 -11.38

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.04 -10.43 -11.38 -11.53 -11.98

MedMira Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

MedMira's Total Equity for the fiscal year that ended in Jul. 2023 is calculated as

Total Equity=Total Assets(Q: Jul. 2023 )-Total Liabilities(Q: Jul. 2023 )
=2.764-14.142
=-11.38

MedMira's Total Equity for the quarter that ended in Jan. 2024 is calculated as

Total Equity=Total Assets(Q: Jan. 2024 )-Total Liabilities(Q: Jan. 2024 )
=3.326-15.307
=-11.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira Total Equity Related Terms

Thank you for viewing the detailed overview of MedMira's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

Progress Update on Securities

By ACCESSWIRE 08-31-2023

MedMira Reports First Quarter Results FY2021

By GlobeNewswire GlobeNewswire 12-25-2020

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test

By ACCESSWIRE ACCESSWIRE 10-14-2022

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019